Stifel analyst Chad Vanacore upgraded Genesis Healthcare to Buy and raised his price target to $2.50 from $2.00. The analyst cites the “stabilization of skilled nursing fundamentals, improving reimbursement outlook, and synergies from restructuring”. Vanacore also points to the “potential margin improvements under new payment model and operating and financial leverage” of Genesis Healthcare.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.